The estimated Net Worth of Barbara Yanni is at least $9.36 mil dollars as of 10 December 2014. Ms. Yanni owns over 1,250 units of Trevena Inc stock worth over $9,363 and over the last 10 years she sold TRVN stock worth over $0. In addition, she makes $0 as Independent Director at Trevena Inc.
Barbara has made over 1 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she bought 1,250 units of TRVN stock worth $5,000 on 10 December 2014.
The largest trade she's ever made was buying 1,250 units of Trevena Inc stock on 10 December 2014 worth over $5,000. On average, Barbara trades about 54 units every 0 days since 2014. As of 10 December 2014 she still owns at least 1,250 units of Trevena Inc stock.
You can see the complete history of Ms. Yanni stock trades at the bottom of the page.
Barbara Yanni J.D. serves as Independent Director of the Company. Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co., a pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation, and tax. Ms. Yanni currently serves on the Board of Directors of Symic Holdings, LLC and Vaccinex, Inc., both private biotechnology companies. Ms. Yanni earned a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University.
Barbara Yanni is 65, she's been the Independent Director of Trevena Inc since 2014. There are 1 older and 15 younger executives at Trevena Inc. The oldest executive at Trevena Inc is Anne Phillips, 66, who is the Independent Director.
Barbara's mailing address filed with the SEC is C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK, PA, 19087.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, ePartners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: